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Aim To investigate whether endothelial lipase (EL) plas-
ma levels are increased in stable coronary artery disease 
(sCAD) and acute coronary syndrome (ACS) patients, as 
well as to test the association of EL plasma levels and the 
severity of CAD and sex.
Methods The study was performed as a single-center, 
cross-sectional, observational research on 72 sCAD and 
187 ACS patients in the Sisters of Charity University Hos-
pital Centre, Zagreb, Croatia, between December 1, 2011 
and December 1, 2012. EL plasma levels were measured 
using ELISA.
Results EL plasma levels were significantly higher in sCAD 
patients (median 311.3 pg/mL, interquartile range [IQR] 
250.4-422.6 pg/mL) than in ACS patients (median = 258.7 
pg/mL, IQR = 162.1-356.0 pg/mL; P < 0.001). EL levels in fe-
male ACS patients were significantly higher (median 314.5 
pg/mL, IQR 218.3-420.8 pg/mL) than in male ACS patients 
(median 225.4 pg/mL, IQR 148.7320.1 pg/mL; P < 0.001) 
and similar to the EL levels in the sCAD patients. There was 
no significant correlation between EL plasma levels and 
the GENSINI score and between EL plasma levels and the 
number of atherosclerotic coronary artery segments in ei-
ther the ACS (rho = -0.09, P = 0.247; rho = 0.12, P = 0.106, re-
spectively) or sCAD group (rho = 0.04, P = 0.771; rho = 0.06, 
P = 0.643, respectively).
Conclusion Our results suggest that EL plasma levels dis-
criminate male but not female patients with different clini-
cal presentations of CAD, as well as female and male ACS 
patients. EL plasma levels are not significantly correlated 
with CAD severity.
Endothelial lipase plasma 
levels are increased in both 
sexes in stable coronary artery 
disease and only in women 
with acute coronary syndrome 
but not associated with the 
severity of coronary artery 
disease
CLINICAL SCIENCE 
 
Croat Med J. 2016;57:482-92 
https://doi.org/10.3325/cmj.2016.57.482
483Trbušić et al: EL plasma levels in CAD patients
www.cmj.hr
Coronary artery diseases (CAD) can cause different clini-
cal presentations compatible with myocardial ischemia/
infarction. They can be divided into two main catego-
ries: stable CAD (sCAD) and acute coronary syndrome 
(ACS), the latter ranging from unstable angina pectoris 
(UAP) to non-ST-segment elevation myocardial infarction 
(NSTEMI) and ST-segment elevation myocardial infarction 
(STEMI). ACS is almost always associated with erosion or 
rupture of atherosclerotic plaque, thrombus formation, 
possible coronary vasospasm, and abrupt reduction of 
coronary blood flow due to partial or complete occlu-
sion of the infarct-related coronary artery (1). The risk of 
plaque erosion or rupture is influenced by intrinsic (vul-
nerability) and extrinsic conditions (local stress due to cy-
clic stretching, compression, flexion, shear, and pressure 
fluctuations). Vulnerability of the atherosclerotic plaque is 
determined by the size of the lipid-rich necrotic core, the 
thickness of the fibrous cap, and the presence of inflam-
mation (2,3).
Endothelial lipase (EL) is a member of the triglyceride li-
pase gene family, expressed by vascular endothelial cells 
(ECs), smooth muscle cells (SMCs), and macrophages (4,5). 
EL is a phospholipase with a high affinity for high-density 
lipoprotein-phospholipids (HDL-PL). By acting on HDL, EL 
alters the structural and functional properties of HDL (6,7), 
as well as HDL plasma levels in mice (8), rabbits (9), and hu-
mans (7,10). EL and bioactive lipids generated by EL-me-
diated cleavage of HDL-PL (11) were identified as strong 
inducers of inflammatory cytokines in macrophages (12) 
and vascular endothelial cells (13).
EL expression can be induced by tumor necrosis factor α, 
interleukin 1β, and biomechanical forces in vascular en-
dothelial cells (14,15), by angiotensin II and hypertension 
in vascular SMCs (16), as well as by lipopolysaccharide in 
macrophages (17).
EL plasma concentrations are strongly associated with C-
reactive protein (CRP) and interleukin 6 (IL-6) levels and 
can be increased by experimentally-induced endotoxemia 
(18,19). EL is highly expressed in advanced human and 
mouse atherosclerotic plaques, primarily by macrophages 
and to a lesser extent by SMCs (20-22). Despite its expres-
sion in atherosclerotic lesions and its capacity to augment 
the secretion of inflammatory cytokines (12,13), neointima 
formation (23), and monocyte adhesion to the vessel wall 
(24), as well as its negative impact on HDL plasma levels 
and functionality (6-8,10), the role of EL in atherogenesis 
is still obscure.
Studies that have so far investigated the impact of EL on 
atherosclerosis in mouse models provided controversial 
results: while EL deficiency in apolipoprotein E-knockout 
mice attenuated the development of atherosclerotic le-
sions in one study (25), in an another study no effect of EL 
deficiency on atherosclerosis development was observed 
in apolipoprotein E- and low-density lipoprotein (LDL) re-
ceptor- knockout mice (26). According to Badelino et al 
(27), human plasma EL concentrations were significantly 
associated with subclinical atherosclerosis. They conclud-
ed that EL may be a pro-atherogenic factor in humans (27). 
Another genetic study revealed that the EL gene polymor-
phism might be associated with ACS (28). However it re-
mained uninvestigated if EL plasma levels are increased in 
patients with different forms of CAD. Considering the posi-
tive association between EL plasma levels and the extent 
of inflammatory state, together with increased EL expres-
sion in atherosclerotic lesions, we hypothesized that EL 
plasma levels would be increased in sCAD due to persist-
ing low-grade inflammation. Further, we also hypothesized 
that EL levels were increased by CAD severity (evaluated by 
the modified GENSINI scoring system and the number of 
stenotic coronary artery segments) and different in men 
and women.
MaTerIalS anD MeThoDS
Study design and patients
This study was designed and performed as an observation-
al, cross-sectional clinical study in the Sisters of Charity Uni-
versity Hospital Centre, Zagreb, Croatia. The ACS patients 
were recruited from the Emergency Department between 
December 1, 2011 and December 1, 2012. The patients 
with suspected sCAD scheduled for coronary angiography 
were recruited from the Department of Cardiology. Written 
informed consent from each patient was obtained prior to 
the enrolment to the study according to the Good Clinical 
Practice and Helsinki Declaration principles (29). The study 
was approved by the Sisters of Charity UHC and Medical 
University of Graz Ethics Committees, in accordance with 
the institutional guidelines.
Inclusion and exclusion criteria
Overall, 226 ACS patients and 111 sCAD patients were 
screened for enrolment. ACS patients were selected 
based on either of the typical unstable symptoms, el-
evation in cardiac markers (creatine kinase, troponine 
I), dynamic changes in electrocardiogram, and/or 
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echocardiographic evidence of new loss of viable myocar-
dium or regional wall motion abnormality (30). Coronary 
angiography was performed in 90% of all suspected sCAD 
and ACS patients using the radial approach and in the rest 
with femoral or brachial approach depending on patient 
individual anatomy. The time interval between arrival to 
the hospital and coronary angiography was in accordance 
with the recommendation of the European Society of Car-
diology (within 2 hours for STEMI patients, 2-72 hours for 
other ACS patients, indefinite for sCAD patients) (31-33).
Exclusion criteria were a patient’s refusal to participate in 
the study and/or to undergo coronary angiography, aller-
gy to intravenous contrast, acute aortic dissection, chronic 
heart failure with ejection fraction (EF) below 40%, chronic 
renal failure with serum creatinine ≥200 mmol/L, a chronic 
autoimmune and/or infectious disease, and decompensat-
ed liver cirrhosis (Child-Pugh class B and C).
Patient characteristics, history, and medication
The patients’ demographic data were recorded by the 
investigator in the data collection form. Special consid-
eration was given to patients’ symptoms in order to de-
termine the CAD type. Previous antihypertensive, statin, 
and antiplatelet treatments and the presence of major 
atherosclerotic risk factors were noted. Heart rhythm was 
determined and blood pressure calculated as the average 
of three measurements. Hypertension was diagnosed ac-
cording to the criteria of the European Society of Cardiol-
ogy (34). Hypertension was defined as systolic blood pres-
sure (SBP)≥140 mm Hg and/or diastolic blood pressure 
(DBP)≥90 mm Hg, and patients’ history of using antihy-
pertensive medications was also considered. Patients with 
diabetes were considered as those with dietary treatment, 
antidiabetic medication, or current fasting plasma glucose 
levels higher than 7.0 mmol/L (35). Hyperlipidemia was 
defined as a low-density lipoprotein (LDL)-cholesterol lev-
el higher than 3.5 mmol/L, or taking a lipid-lowering drug. 
Patients were classified as current smokers (smoking more 
than five cigarettes per day within the past 3 months) or 
non-smokers.
Coronary angiography
Angiographic films were reviewed visually by two in-
dependent interventional cardiologists blinded to the 
patients’ clinical information. The mean of two mea-
surements was calculated for each patient. The CAD 
severity was evaluated using 1) the number of 
stenotic coronary artery segments (36) and 2) the modi-
fied GENSINI scoring system (37).
The modified GENSINI scores were derived as described 
previously (38). Briefly, the number of lesions, their se-
verity, and their respective locations were evaluated. The 
coronary vasculature was divided into 27 segments, and 
each segment was graded from 0.5 to 5.0, reflecting the 
importance of location, ie, yielding the location score. The 
severity was scored as follows: <25% = 2; 26% to 50% = 4; 
51% to 75% = 8; 76% to 90% = 16; 91% to 99% = 32; total 
occlusion = 64. The product of the severity score and loca-
tion score constitutes the score for any given segment, and 
their sum makes up the score for a given subject.
laboratory assays
Blood samples were collected immediately at hospital ar-
rival for ACS patients. For sCAD patients, blood was collect-
ed in the morning following hospitalization after overnight 
fasting. The average time from the onset of symptoms 
(pain) to arrival to hospital for ACS patients with ST eleva-
tion myocardial infarction was 215 minutes. For other ACS 
patients (NSTEMI and UAP) the time was longer (hours to 
days) and sometimes not easy to determine because of 
the nature of the clinical presentation (repetitive pain).
After blood sampling, laboratory measurements were im-
mediately performed and plasma samples were frozen at 
-30°C for further EL and IL-6 analysis. The routine laboratory 
measurements were performed on an automated, multi-
channel selective analyzer Modular (Roche Diagnostics, 
Mannheim, Germany). IL-6 concentrations were measured 
using a specific chemiluminescent ELISA (QuantiGlo; R&D 
Systems, Wiesbaden-Nordenstadt, Germany) and EL pro-
tein levels by Human Endothelial Lipase Assay Kit (TaKaRa, 
Takara Bio Europe S.A.S., Saint-Germain-en-Laye, France), 
according to the manufacturer’s instructions.
Statistical analysis
Normality of data distribution was assessed using Smirnov-
Kolmogorov test, and appropriate nonparametric tests 
were used. Differences in categorical values between the 
ACS and sCAD groups were analyzed using χ2 test. Differ-
ences in quantitative values between the ACS and sCAD 
were analyzed using Kruskal-Wallis test, and for individual 
group differences using Mann-Whitney U test and Bonfer-
roni correction where appropriate. Spearman’s Rho non-
parametric test was used to measure the strength of cor-
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relation between two variables. Ordinary least squares 
(OLS) regression was used to determine the predictors of 
EL plasma levels. The OLS regression model was statisti-
cally significant (P < 0.001) with 15.6% of explained EL vari-
ance (r2). P values below 0.05 were considered significant 
except for multiple comparisons where the significance 
was dependent on the number of simultaneously tested 
hypotheses. The data analysis software system IBM SPSS 
Statistics, version 21.0 (IBM, Armonk, NY, USA), was used in 
the statistical analyses.
reSulTS
Sample size and clinical characteristics
Out of 226 ACS patients and 111 sCAD patients assessed 
for eligibility, 39 patients from each group were excluded 
due for the presence of exclusion criteria (Figure 1). The final 
study population included 187 ACS and 72 sCAD patients.
sCAD and ACS groups did not differ significantly in age, 
sex, and body mass index (BMI) (Table 1). In the ACS group 
there were significantly more smokers, whereas in the 
sCAD group there were more diabetics and patients with 
present or treated hyperlipoproteinemia (Table 1). The 
mean arterial pressure (MAP) and left ventricle (LV) EF were 
significantly lower in ACS than in sCAD group (Table 1). 
ACS and sCAD groups did not differ in the number of seg-
ments, whereas the GENSINI score was significantly higher 
in the ACS group (P < 0.001) (Table 1). The 30-day mortal-
ity rate was higher in the ACS than in the sCAD group (4.8 
vs 0%), but not significantly (P = 0.054). There were more 
men in both the ACS and sCAD group (Supplementary Ta-
ble 1). In the ACS group significantly more men than wom-
FIgure 1. Flowchart of the study. Patients (Pts).
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en were smokers and significantly more women than men 
were treated with ASA (Supplementary Table 1). In the 
sCAD group MAP was significantly higher in women than 
in men (Supplementary Table 1).
laboratory parameters
Glucose levels, total cholesterol levels, and LDL-cholesterol 
levels were significantly higher in ACS than in sCAD group 
(P < 0.001) (Table 2). HDL-cholesterol and triglyceride levels 
were similar in the sCAD and ACS patients (Table 2). There 
was no significant difference in high-sensitive C-reactive 
protein (hsCRP) levels between the ACS and sCAD pa-
tients, whereas IL-6 levels were significantly higher in ACS 
patients (Table 2).
Importantly, EL plasma levels were significantly higher in 
sCAD than in ACS patients-(Table 2). This finding, namely 
normal EL levels in ACS patients, prompted us to investi-
gate the predictors of EL levels in sCAD and ACS.
Predictors of el plasma levels in sCaD and aCS patients
The OLS regression model, which included both ACS and 
sCAD patients, identified that belonging to the ACS group 
was a negative predictor of EL plasma levels, whereas both 
TaBle 1. Clinical characteristics and medications*
aCS (n = 187) sCaD (n = 72)
age (years); median (IQr)  65.0 (55.0-76.0) 64.0 (56.0-71.0)
Sex; n (%)
men 129 (69.0) 46 (63.9)
women  58 (31.0) 26 (36.1)
Diabetes mellitus; n (%)†  27 (14.4) 22 (30.6)
hyperlipoproteinemia; n (%)‡  50 (26.7) 33 (45.8)
Smoking cigarettes; n (%)§  68 (36.4) 16 (22.2)
MaP (mmhg); median (IQr)ǁ  90.0 (80.8-96.7) 96.7 (92.1-106.7)
BMI (kg/m2); median (IQr)  28.0 (25.1-31.0) 27.2 (25.1-30.1)
lV eF (%); median (IQr)¶  50.0 (46.5-55.0) 60.0 (54.8-60.0)
number of segments; median (IQr)   2.0 (1.0-4.0)  2.0 (2.0-4.0)
genSInI score; median (IQr)**  48.0 (32.0-80.0) 27.0 (10.3-39.5)
aSa before hospitalization; n (%)  40 (22.0) 48 (66.6)
Statins before hospitalization; n (%)  34 (18.7) 39 (54.1)
*IQr – interquartile range; MaP – mean arterial pressure; BMI – body mass index; lV eF – left ventricular ejection fraction; aCS – acute coronary 
syndrome; sCaD – stable coronary artery disease; aSa – acetyl salicylic acid.
†χ2, P = 0.003.
‡χ2, P = 0.003.
§χ2, P = 0.029.
IIP < 0.001 Mann-Whitney u test.
¶P < 0.001 Mann-Whitney u test.
**P < 0.001 Mann-Whitney u test.
TaBle 2. laboratory results*
group aCS (n = 187) M (IQr) sCaD (n = 72) M (IQr) P (Mann-Whitney u test)
Total cholesterol (mmol/L)   5.3 (4.4-6.2)   4.8 (3.7-5.5) <0.001
LDL-cholesterol (mmol/L)   3.5 (2.8-4.2)   2.8 (2.0-3.8) <0.001
HDL-cholesterol (mmol/L)   1.1 (0.9-1.3)   1.1 (0.9-1.2) 0.909
Glucose (mmol/L)   7.8 (6.5-10.2)   5.9 (5.1-7.7) <0.001
Triglycerides (mmol/L)   1.4 (1.0-2.1)   1.5 (1.1-2.2) 0.233
hsCRP (μg/mL)   3.7 (1.6-7.1)   2.3 (1.4-5.1) 0.057
IL-6 (pg/mL)   6.3 (4.3-14.2)   3.0 (2.0-5.6) 0.001
EL (pg/mL) 258.7 (162.1-356.0) 311.3 (250.4-422.6) <0.001
*aCS – acute coronary syndrome; sCaD – stable coronary artery disease; M – median; IQr – interquartile range; hsCrP – high sensitivity C-reactive 
protein; Il-6 – interleukin-6; lDl – low-density lipoprotein; hDl – high-density lipoprotein; el – endothelial lipase.
487Trbušić et al: EL plasma levels in CAD patients
www.cmj.hr
hsCRP and female sex were positive predictors of EL plas-
ma levels (Table 3).
Sex markedly impacts the el and hsCrP plasma levels 
in aCS patients, but not in sCaD patients
To examine how sex impacts EL plasma levels, we com-
pared EL levels in female and male sCAD and ACS patients. 
We found a evident sex difference in the ACS group, name-
ly, significantly higher EL levels in female ACS patients than 
in male ACS patients (P < 0.001) (Figure 2A). In sCAD pa-
tients EL levels were not significantly different between 
women and men (Figure 2A). EL levels in female ACS pa-
tients were similar to the levels in female sCAD patients, 
whereas the levels in male ACS patients were significantly 
lower than in male sCAD patients (Figure 2A). Similarly as 
for EL, hsCRP plasma levels were also significantly higher 
in female than in male ACS patients (P < 0.001), with no 
sex differences in sCAD patients (P = 0.841) (Figure 2B). IL-6 
plasma levels were higher in female ACS patients than in 
male ACS patients, however, without reaching statistical 
significance (Figure 2C). Glucose plasma levels and plasma 
lipids except HDL-cholesterol, which was significantly high-
er in ACS women than in men (men: median 1.1 mmol/L, 
TaBle 3. Predictors of endothelial lipase plasma levels*
unstandardized coefficients Standardized coefficients 95% confidence Interval for B
B standard error beta t lower bound upper bound P
(Constant) 295.08 113.20 2.61 72.02 518.14 0.010
ACS group -104.23 29.49 -0.25 -3.53 -162.32 -46.14 <0.001
Age (years) 1.71 1.07 0.10 1.59 -0.40 3.82 0.112
Female sex 63.58 27.02 0.16 2.35 10.36 116.81 0.019
hsCRP (mg/L) 1.16 0.40 0.18 2.92 0.38 1.93 0.004
Total cholesterol (mmol/L) -15.40 22.58 -0.11 -0.68 -59.87 29.07 0.496
HDL-cholesterol (mmol/L) -33.59 34.40 -0.07 -0.98 -101.35 34.16 0.330
LDL-cholesterol (mmol/L) 7.78 22.04 0.05 0.35 -35.64 51.21 0.724
Triglycerides (mmol/L) 7.19 13.27 0.04 0.54 -18.96 33.33 0.589
Glucose (mmol/L) 4.96 2.95 0.11 1.68 -0.86 10.78 0.094
MAP (mmHg) -0.78 0.87 -0.06 -0.90 -2.50 0.93 0.370
*aCS – acute coronary syndrome; sCaD – stable coronary artery disease; hsCrP – high sensitive C-reactive protein; hDl – high density lipoprotein; 
lDl – low density lipoprotein; MaP – mean arterial pressure
FIgure 2. endothelial lipase (el), high sensitivity C-reactive protein (hsCrP), and interleukin-6 (Il-6) levels in the study groups: (A) 
el and (B) hsCrP protein levels were measured in the serum of 46 stable coronary artery disease (sCaD) men, 26 sCaD women, 129 
aCS men, 58 acute coronary syndrome (aCS) women, by elISa. P ≤ 0.0083 was considered statistically significant. (C) Il-6 protein 
levels were measured in the serum of 46 sCaD men, 26 sCaD women, 129 aCS men, and 58 aCS women by elISa. P ≤ 0.0125 was 
considered statistically significant. The boundaries of the box indicate the lower and upper quartiles, the horizontal line the median 
and the error bars the 95% confidence interval.
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IQR 0.9-1.3 mmol/L; women: median: 1.2 mmol/L, IQR 1.0-
1.4 mmol/L, P = 0.007), were similar in men and women in 
both groups (not shown).
relationship between el levels and inflammatory 
markers
We found no correlation between EL levels and hsCRP in 
either sCAD or ACS patients. However, when the corre-
lations were examined in women and men separately, a 
strong significant correlation between EL and hsCRP lev-
els was observed only in female ACS patients (rho = 0.361, 
P = 0.005). There was no correlation between EL and IL-6 
plasma levels (not shown).
relationship between el levels and CaD severity
We found no correlation between EL plasma levels and the 
GENSINI score, and no correlation between EL plasma lev-
els and the number of atherosclerotic coronary artery seg-
ments in either the ACS (rho = -0.09, P = 0.247; rho = 0.12, 
P = 0.106, respectively) or sCAD group (rho = 0.04, P = 0.771; 
rho = 0.06, P = 0.643, respectively).
DISCuSSIon
The main finding of this study is that EL plasma levels were 
increased in both sexes in sCAD and were not correlat-
ed with CAD severity evaluated by the modified GENSINI 
scoring system and the number of stenotic coronary artery 
segments. However, EL plasma levels were increased only 
in women with ACS.
Given the role of HDL in the pathogenesis of atheroscle-
rosis (39-41), together with the established impact of EL 
on HDL metabolism (7,8) and the positive relationship be-
tween EL and inflammation (18), EL is considered to be a 
proatherogenic molecule. In our previous work we dem-
onstrated a higher EL protein expression in symptomatic 
and unstable carotid plaques, compared with the plaques 
found in patients without neurological symptoms and 
with a stable plaque phenotype (22). Furthermore, in pa-
tients with significant carotid artery stenosis, EL plasma 
levels were higher in the symptomatic than in the asymp-
tomatic group (42).
Considering the positive relationship between EL plas-
ma levels and the extent of inflammatory state (18,19), 
as well as coronary (27) and carotid atherosclerosis (22), 
we hypothesized that EL plasma levels were different 
in different clinical presentations of CAD and were related 
to CAD severity. We hypothesized that EL plasma levels 
would be increased in sCAD due to persisting low-grade 
inflammatory state. Although the relative contribution of 
coronary compared to systemic endothelium in terms of 
EL production is rather small, it is possible that compro-
mised endothelial function in acute compared to chronic 
forms of CAD was at least in part responsible for decreased 
EL levels in ACS. The initial data analyses revealed signifi-
cantly higher EL levels in the sCAD group, which also had 
significantly lower IL-6 levels compared to the ACS group. 
This was contradictory to previous studies showing the 
positive relationship between EL and acute inflammatory 
markers, such as IL-6 and hs-CRP (18,19).
The most striking and interesting finding of the present 
study emerged upon addressing the role of sex in the 
determination of EL levels in sCAD and ACS patients. We 
found increased EL levels in female ACS patients, similar 
to the levels in sCAD patients, but markedly lower EL lev-
els in male ACS patients. This observation, together with 
the higher prevalence of men (69%) having low EL levels in 
the ACS group. explains the low EL levels in that group. To 
our knowledge this is the first report on a sex-related differ-
ence in EL plasma levels in ACS patients. Besides EL, hsCRP 
plasma levels were also higher in female ACS patients than 
in male ACS patients. Although hormone replacement 
therapy might at least in part explain the increased hsCRP 
levels (43) in women with ACS, the responsible underly-
ing mechanism remained unexplained (44,45). Our results 
add a new piece of evidence to the long list of sex differ-
ences in CAD patients (44,46). It remains to be determined 
whether EL plasma concentration might be a useful bio-
marker for risk stratification and/or choice of therapeutic 
approaches for patients with ACS. We speculate this might 
be due to prolonged endothelial damage of small coro-
nary vessels in women.
Interestingly, although EL plasma levels correlated with 
hsCRP levels in previous studies (19,47), we found a signifi-
cant correlation only in the female ACS patients with in-
creased both EL and hsCRP. It is not clear why correlations 
were not found in other groups. One can speculate that 
the simultaneous response of both EL and hsCRP to acute 
inflammatory stimuli, as in female ACS patients, is required 
to observe a relationship. Furthermore, the lack of associa-
tion between EL and inflammatory markers in the present 
study may be due to the disruption of the association by 
medication (48). In contrast to previous studies where EL 
levels and inflammatory markers were determined in the 
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plasma (19,47), we measured them in the serum. In light of 
previous findings showing different hsCRP levels in plasma 
and serum prepared from the same blood (49), it remains 
to be established whether the experimental procedure 
disrupts the association between EL and inflammatory 
marker levels.
In the present study EL levels did not correlate significantly 
with HDL-C levels either in sCAD or ACS patients. The lack of 
association between EL and HDL-C levels might be partially 
explained by the fact that high levels of EL mass, as mea-
sured by ELISA, do not necessarily have to be accompanied 
by increased plasma EL activity, considering the reduced 
phospholipase activity of various genetic variants (7,10).
More importantly, the mass of cholesterol that is carried by 
the HDL particles, ie, HDL-cholesterol, is not a sensitive pa-
rameter of the atheroprotective properties of HDL. Rather, 
the direct measurement of HDL function (50) or the assess-
ment of HDL particle concentrations is a much better esti-
mation of the cardioprotective properties of HDL. Indeed, 
HDL functionality, but not HDL-cholesterol levels, has been 
demonstrated to predict long-term mortality (51). Of note, 
EL was found to reduce the functionality of HDL (7). There-
fore, the lack of association between EL and HDL-choles-
terol levels has no significance, because the important pa-
rameter is the EL-induced alteration of HDL functionality.
In the present study we found no significant correlation 
between EL plasma levels and CAD severity, evaluated by 
the GENSINI score and by quantifying the number of dis-
eased segments of the coronary artery. In patients with 
significant carotid stenosis, we previously found that the 
intensity of the plaque EL immunostaining was related to 
plaque vulnerability but not associated with EL plasma lev-
els (22,42). Accordingly, it is likely that in coronary artery 
plaques of sCAD and ACS patients, like in carotid plaques, 
EL expression levels in coronary atherosclerotic lesions are 
related to CAD severity, but that the augmented local EL 
expression does not contribute significantly to the overall 
EL abundance in plasma. Therefore, in the present study the 
dissociation between local and systemic EL levels might be 
responsible for the lack of association between EL levels 
and CAD severity. Considering the association of EL plasma 
levels with atherogenic lipid profile (27), together with im-
proved functionality of HDL in individuals with genetically 
decreased EL plasma levels (52,53), EL should be consid-
ered a potential therapeutic target in dyslipidemia. How-
ever, in this study HDL-C and triglycerides levels did not 
differ between sCAD and ACS patients.
Both diabetes mellitus type 2 and hyperlipoproteinemia, 
which had higher prevalence in the sCAD patients, might 
have contributed to higher EL levels in this group due to 
their association with low-grade chronic inflammation. 
Furthermore, both ASA and statins, more frequently used 
before hospitalization in sCAD patients, might have addi-
tionally impacted EL levels (54).
The main study strength is its comprehensive design as a 
single-center observational and non-interventional study, 
with a highly structured protocol and predefined statisti-
cal analyses. However, the main limitation of this study was 
the sample size of the sCAD group which was modest and 
therefore our ability to definitely evaluate the association 
between EL plasma levels and CAD severity in the sCAD 
group was limited.
Based on our results we conclude that EL plasma levels 
discriminate male patients with different clinical presenta-
tions of CAD, ie, sCAD and ACS, as well as female and male 
ACS patients. EL plasma levels are not related to CAD sever-
ity. It remains to be determined whether EL might provide 
prognostic information on the development of cardiovas-
cular events or predict the outcome in patients with ACS, 
particularly in women, in whom the diagnosis and risk as-
sessment of CAD is reportedly more difficult than in men.
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